Introduction
Three classes of FccRs for IgG (I, II, and III) are expressed by human leukocytes [1, 2] . As FccRI (CD64) binds to monomeric IgG, it is usually saturated in the presence of serum. FccRII (CD32) and III (CD16) bind to aggregated IgG, typically in the form of immune complexes (ICs) or IgG-opsonized targets. FccRI, IIA, IIIA, and IIIB activate cellular responses, whereas FccRIIB inhibits cell responses. FccRIIA is the most highly expressed FccR. It is also the only receptor for human IgG2, the most common autoantibody isotype [3] . Hence, FccRIIA is a potential contributor to IC-related diseases, such as arthritis.
Several lines of evidence indicate that FccRIIA plays an important role in rheumatoid arthritis (RA). For example, FccRIIA polymorphisms correlate with several chronic inflammatory diseases, including RA [3] . Disease severity correlates with FccRIIA expression levels [4, 5] . Importantly, blockade of FccRIIA, but not FccRIII, inhibits TNF-a production by monocytes in response to precipitated human ICs [6, 7] . Animal studies also support the role of FccRIIA in arthritis. However, as rodents lack an ortholog of human FccRIIA, it is difficult to directly compare murine and human studies. Importantly, Hogarth and colleagues have used human FccRIIA-transgenic mice to demonstrate an important role of FccRIIA in a humanized animal model of collagen-induced arthritis [8] . FccRIIA-transgenic mice exhibit spontaneous autoimmune disease and are hyperresponsive to pathogenic antibodies [3, 8] . Also in the murine system, gene knock-out experiments have shown that activating FccRs directly mediate cartilage destruction [9] and that the development of arthritis does not require the presence of the murine orthologs of the activating FccRI and III [10] . Hence, FccRIIA has emerged as a leading target for new drug candidates, including therapeutics aimed at the extracellular region of FccRIIA [3, 11] . While FccRIIA's extracellular region mediates IC recognition, its intracellular C-terminal domain plays a key role in signal transduction [12] . The cytoplasmic domain contains the ITAM (immunoreceptor tyrosine-based activation motif) consensus sequence YxxLx (5) (6) (7) (8) (9) (10) (11) (12) Yx (2) (3) L/I. Phosphorylated tyrosine residues of ITAMs are high affinity binding sites for Syk, a tyrosine kinase that participates in phagocytosis. In addition to phagocytosis, FccRIIA's cytoplasmic tail also mediates phagolysosome formation, the delivery of lysosomal contents to the phagosome or, in the context of frustrated phagocytosis, the extracellular release of lysosomal contents. We have discovered that the tripeptide LTL sequence is a key mediator of phagolysosomal fusion [12, 13] . Modification of the LTL sequence to an AAA sequence dramatically reduces phagolysosome formation. AAA was chosen due to the residues having similar properties of hydropathy and linearity, and a three residue sequence being too short to scramble. Although the LTL sequence bears some resemblance to the dileucine lysosomal signal sequence found in other pathways [14] , the LTL sequence is highly specific for FccRIIA.
To further examine the mechanism by which FccRIIA's cytoplasmic LTL sequence affects cell physiology and to test the potential therapeutic role of LTL-containing peptides in cells, it is necessary to use cell-penetrating peptides. Recently, several cell-penetrating peptides, which are cationic in nature, have been developed [15] [16] [17] [18] [19] [20] . Penetratin is a typical cell-penetrating Trojan peptide; it is a 16 amino acid peptide derived from the third helix of the Drosophila transcription factor Antennapedia, corresponding to residues 43-58 of the homeodomain [17] . This peptide has the ability to translocate across cell membranes in a concentration-, energy-, and endocyosisindependent manner [17] [18] [19] [20] . Importantly, penetratin is able to transport covalently attached molecules, such as oligonucleotides and oligopeptides, into cells [17] [18] [19] [20] . These ''Trojan" peptide constructs may become useful as delivery vehicles for therapeutic compounds. We now show in live human neutrophils that it is possible to reduce Ca 2+ signaling and phagolysosome fusion by treatment with a Trojan peptide construct.
Materials and methods

Materials
Indo-1-AM, pluronic-127, cell media, phosphate-buffered saline (PBS), LysoTracker Red DND-99, and LysoTracker Green DND-26 were obtained from Invitrogen Corp. (Carlsbad, CA). Cover-glass bottom dishes were purchased from MatTek Corporation (Ashland, MA). Unless otherwise noted, chemicals were obtained from Sigma Chemical Company (St. Louis, MO).
Trojan peptide synthesis
Trojan peptides contained the penetratin sequence in tandem with a portion of the cytoplasmic domain of the FccRIIA receptor (Fig. 1) . For use as a control, a second peptide was constructed in which the LTL motif was substituted with AAA sequence. To visualize these peptides, the Trojan-LTL and Trojan-AAA peptides were conjugated to tetramethylrhodamine and fluorescein, respectively. Custom peptides were prepared by Bio-Synthesis, Inc. (Lewiston, TX). Peptides were purified by HPLC and confirmed by mass spectroscopy. Peptides were stored in sterile PBS at À20°C.
Isolation of human neutrophils
Peripheral blood was collected from healthy human donors in compliance with the guidelines of the University of Michigan Institutional Review Board for Human Subject Research. Neutrophils were isolated from peripheral blood using Ficoll-Histopaque density gradient centrifugation (Sigma Chemical Co., St. Louis, MO). Samples were re-suspended and then washed in PBS by centrifugation.
Fluorescence microscopy of peptides
Poly-D-lysine coated cover slips for Trojan peptide fluorescence microscopy experiments were prepared by incubating cover slips with 0.01% (w/v) poly-D-lysine for 1 h at 37°C followed by washing with PBS. Neutrophils were allowed to adhere to poly-lysinecoated cover slips for 15 min at 37°C. Adherent neutrophils were labeled at 37°C for 1 h with the Trojan-LTL peptide (45 lM), control peptide (45 lM), or ER Tracker (Invitrogen; 50 lM) in PBS.
ER Tracker, a fluorescent dye, has been shown to label the endoplasmic reticulum [21] . Cover slips were washed with PBS and imaged on a Ziess Axiovert 135 inverted microscope coupled to an intensified charge coupled device camera (QImaging, Barnaby, BC, Canada). Cover slips were observed using bright field and fluorescence microscopy. To detect fluorescein, excitation and emission filters at 482 and 530 nm were used. For ER Tracker bluewhite DPX, optical filters with excitation at 364 nm and emission at 520 nm were used. To image tetramethylrhodamine, excitation and emission filters at 535 and 590 nm, respectively, were employed. Images were obtained using Volumescan (Vaytek, Inc., Fairfield, IA) and were processed using Image-Pro Plus (Media Cybernetics, Silver Spring, MD) and MicroTome Deconvolution software (Vaytek, Inc.).
Phagocytosis of targets
Neutrophils were labeled with Trojan-LTL or -AAA peptide at 45 lM. Sheep red blood cells (SRBCs) were opsonized with rabbit anti-sheep erythrocyte IgG antibody by using the highest subagglutinating dilution of antibody. IgG-coated erythrocytes (EAs) or untreated latex beads (Sigma) were added to cover slips with adherent neutrophils at a ratio of 10:1 (target/effector) and incubated for 45 min at 37°C in PBS. Peptide-treated neutrophils were labeled with LysoTracker Red DND-99 (for fluorescein-Trojan-AAA peptide) or LysoTracker Green DND-26 (for tetramethylrhodamine-Trojan-LTL peptide) at 20 lM in PBS for 5 min at 37°C (Invitrogen). The LysoTracker dyes have been shown to localize in lysosomes and phagolysosomes [22] . In experiments involving EAs, the coverslips were moved to 4°C to stop phagocytosis, and external EAs were distinguished from internal EAs by labeling with a secondary fluorescent anti-IgG (internalized EAs are not labeled).
Imaging of phagosome-associated Ca
2+
For Ca 2+ experiments, neutrophils were loaded with Indo-1-AM (14 lM) for 45 min at 37°C. Cells were washed and then labeled with Trojan-LTL or -AAA peptides (45 lM) for 15 min at 37°C. EA were added to samples at a 10:1 ratio followed by a further incubation for 20 min at 37°C. Cells were washed by centrifugation, re-suspended in imaging buffer [23] and then allowed to adhere to cover slips for 20 min at 37°C. Afterwards, the cover slips were washed to remove unbound EA, then incubated for a further 1 h and 40 min. Imaging was performed using a 37°C heated microscope stage. Fluorescence excitation was provided by a 100 W mercury lamp. Samples were imaged using a Princeton Instruments PIMax II intensified charge coupled device detector coupled to a Dual-View emission-splitting device (Optical Insights, Tuscon, AZ) attached to a side port of a Nikon TE-2000-U microscope. Fig. 1 . Trojan peptide constructs. Trojan peptides contained the cell-permeable penetratin sequence of Antennapedia in tandem with the C-terminal end of FccRIIA's cytoplasmic domain. The penetratin sequence is underlined, and the Fc receptor sequence is in bold type with its critical motif highlighted. As a control, a peptide was constructed in which the LTL motif was substituted with AAA. The peptide containing the LTL motif (Trojan-LTL peptide) was conjugated to tetramethylrhodamine whereas the AAA substituted (Trojan-AAA) peptide was labeled with fluorescein. Prior to use, the lyophilized peptides were dissolved in a stock solution with sterile PBS at a concentration of 900 lM, and stored at À20°C. Prior to use peptides were diluted to a concentration of 45 lM.
Indo-1-labeled samples were excited using a D350/50x filter and a 380 nm dichroic beamsplitter (Chroma High Ca 2+ phagosomes were scored as those that had a higher Ca 2+ ratio in the phagosome than in the cell body; whereas those with equal or lower Ca 2+ ratio were scored as low.
Results
Trojan peptides containing FccRIIA's tail bind of to an ER-like structure of human neutrophils in an LTL-dependent fashion
In this paper, we test the hypothesis that the tail of FccRIIA can interfere with physiological processes in living neutrophils. To address this hypothesis, it is necessary to first ascertain if Trojan peptides containing FccRIIA tail sequences are capable of entering neutrophils. To observe the intracellular accumulation and distribution of Trojan peptides, neutrophils were incubated with labeled peptides and then imaged by fluorescence microscopy. The Trojan-LTL peptide accumulated within the cytoplasm of cells (Fig. 2B) . The intracellular distribution of the Trojan-LTL peptide appeared to resemble that of the endoplasmic reticulum (Fig. 2B) , as suggested by the intracellular labeling pattern of the dye ER Tracker (Fig. 2D) . In contrast, cells labeled with the Trojan-AAA peptide did not show specific sub-cellular accumulation, only a diffuse intracellular labeling pattern was observed throughout the cells (Fig. 2F) ; this suggests that the LTL sequence of the Trojan-LTL peptide promoted specific delivery to a cell compartment resembling the ER. As expected, these results demonstrate that peptides containing the penetratin leader sequence cross the neutrophil's plasma membrane, as has been previously demonstrated in many cell types [17] [18] [19] [20] . Furthermore, sub-cellular accumulation of Trojan-LTL peptides suggests that FccRIIA's tail may have a binding site associated with the ER, and the LTL motif may be involved in this interaction.
LTL labeling patterns during phagocytosis
The fluorescent tag on the Trojan-LTL peptide enabled us to visualize its distribution during phagocytosis. The Trojan-LTL peptide accumulated at sites of EA binding prior to internalization (Fig. 3A and B) . Interestingly, the Trojan-LTL peptide was found about the perimeter of EAs after internalization ( Fig. 3C and D) . On the other hand, cells stained with the Trojan-AAA peptide did not display preferential localization during phagocytosis ( Fig. 3E  and F) . To determine if Trojan-LTL peptide accumulation near targets was specific for antibody-dependent events, experiments were performed with non-opsonized erythrocytes and latex bead targets. In the absence of IgG, no binding or internalization of erythrocyte targets was observed. However, phagocytosis of latex beads was observed in the absence of IgG (data not shown). In these experiments, there was no detectable shift in Trojan-LTL peptide localization to targets. As in the antibody-dependent experiments described above, there was no detectable change in the Trojan-AAA peptide accumulation using a latex bead target (Fig. 4) . Thus, Trojan-LTL peptide redistribution is not a general feature of phagocytosis. was dramatically reduced to 17 ± 5.7% (Fig. 5A ). Representative images of Trojan-AAA ( Fig. 5B and C) and -LTL (Fig 5D and E) treated cells are shown. These data were further quantified using line profile analysis, as shown in Fig. 5F . As these data show, the calcium ratio is higher in the region of the phagosome for Trojan-AAA peptide-treated cells. Thus, cells treated with Trojan peptides incorporating the tail region of FccRIIA demonstrate reduced Ca 2+ signaling in the vicinity of phagosomes.
Incubation with the Trojan-LTL peptide reduces
The Trojan-LTL peptide reduces phagosome-lysosome fusion
To test the hypothesis that Trojan-LTL peptide treatment influences phagolysosome formation, neutrophils were treated with Trojan-AAA or -LTL peptides then incubated with EA. To assess phagolysosome formation, cells were labeled with LysoTracker. Untreated cells and cells treated with the Trojan-AAA peptide display fusion of lysosomes with phagosomes at indistinguishable rates of 74 ± 4.0% and 73 ± 4.9%, respectively (Fig. 6A) . Representative micrographs illustrating phagolysosome formation in Trojan-AAA-treated cells are shown in Fig. 6B and C. In contrast, cells treated with the Trojan-LTL peptide display a greatly reduced rate of phagolysosome formation of 25 ± 1.7% (Fig. 6A, D, and E) . This suggests that the Trojan-LTL peptide blocks the downstream function of phagolysosome formation. Phagolysosome formation was also quantitatively confirmed using line profile analysis, which is illustrated in Fig. 6F . In contrast to the Trojan-LTL-treated cells, a bright rim of fluorescence is observed about the perimeter of the target EA in Trojan-AAA-treated cells indicating that phagolysosome formation has taken place. B-E, 1000Â; B and C, n = 5; D and E, n = 4).
Discussion
In this study, we have developed a novel Trojan peptide containing the cytoplasmic tail sequence of FccRIIA that affects both antibody-dependent signal transduction and phagolysosome formation. These results are in accordance with previous molecular biological findings showing that the tail of FccRIIA plays an important role in promoting phagolysosome formation [12] and that the LTL motif within the tail is crucial in regulating this activity [13] . Specifically, CHO cells expressing the wild-type FccRIIA were capable of mediating antibody-dependent phagolysosome formation whereas transfectants expressing a mutant form in which the LTL motif had been replaced with a AAA sequence were competent to phagocytose, but not to form phagolysosomes. Our present study using human neutrophils demonstrates that the addition of exogenous FccRIIA tail domains to a cell suppresses phagolysosome formation, perhaps by acting as a molecular decoy for effector molecules.
Previous studies have illustrated the value of cell membranepermeable peptides (for reviews see Refs. [17] [18] [19] [20] ), including their role as a delivery system to affect biological signal transduction. For example, a cell-permeable peptide containing the growth factor receptor binding protein 2 (Grb2) binding site of the epidermal growth factor (EGF) receptor selectively inhibited growth factorstimulated mitogenesis [24, 25] . Moreover, a cationic peptide containing the phosphatidylinositol 4,5-bisphosphate binding region of gelsolin interfered with actin assembly and neutrophil motility [26] . This study extends the Trojan peptide field by showing that Trojan peptides can influence phagosome-associated signals and the ability of cells to carry out antibody-dependent phagolysosome formation.
Using fluorescent Trojan peptides, we have shown that LTL-containing peptides, but not AAA-containing peptides, accumulate at intracellular sites resembling the ER. As microtubules interact with the ER and help determine its shape [27] , some similarity in distribution to these structures may also be observed. In addition, fluorescent Trojan-LTL peptides, but not AAA-containing peptides, are selectively enriched at sites of phagocytosis. Although the ER's role in regulating phagolysosome formation is highly speculative, recent studies have demonstrated the accumulation of ER-related proteins at phagosomes or phagocytotic cups [28] . One possible interpretation of our findings is that a binding site for FccRIIA's cytoplasmic domain may exist in the ER. We speculate that the Trojan-LTL peptide may compete with the cell surface FccRIIA for this receptor site, thus interfering with normal cell function.
A well-known precedent for plasma membrane-to-ER communication during immunological events is capacitative Ca 2+ signaling, which has been linked with antibody-dependent effector functions [29] . Previous studies have shown enhanced intercellular free Ca 2+ in the periphagosomal area of human neutrophils [30] . Under control conditions, we have also observed enhanced Ca 2+ signaling in the vicinity of phagosomes, which is dramatically reduced or eliminated in the presence of Trojan-LTL peptides. This reduction in Ca 2+ signaling could be mediated by perturbed ER-to-plasma membrane cooperation. Although Ca 2+ signaling is not a requirement for phagocytosis, it plays a central role in phagolysosome fusion and degranulation. Hence, we suggest that the Trojan-LTL peptide-mediated disruption of Ca 2+ signaling is an important contributor to the reduction of phagolysosome formation. Our long-range goal is to develop therapeutic peptides that diminish the capacity of FccRIIA to mediate tissue damage in arthritis [3] [4] [5] [6] [7] [8] [9] [10] [11] ; the present study is an important step in this direction. Therapeutic peptides are the most rapidly growing segment of the pharmaceutical market. Currently, there are 40 therapeutic peptides marketed and prescribed worldwide including vancomycin, cyclosporine, fuzeon, integrillin, oxytocin, lypressin, sandostatin, glatiramer, and desmopressin. Currently marketed peptides are used to treat many different clinical indications. Another 270 peptides are in clinical tests while 400 are in advanced pre-clinical studies [31] . We speculate that it may be possible to construct therapeutic LTL-containing peptides to reduce FccRIIAmediated phagolysosome formation and degranulation by human leukocytes [1, 2] and synovial lining cells [32] .
In summary, we have treated living cells with a peptide that selectively blocks phagosome-associated Ca 2+ signaling and diminishes phagolysosome formation in response to IgG-opsonized targets. The specificity of the Ca 2+ inhibition suggests that this approach might be useful in drug development. Therapeutic pep- tides containing the LTL motif may reduce phagolysosome formation and the release of degradative lysosomal enzymes in vivo, thereby diminishing tissue damage in arthritis. As these peptides are too costly for animal trials, we are presently engineering more economical peptide-based compounds for future in vivo studies.
